A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir

Archives of Virology

Volumn 157, Issue 2, 2012, Pages 285-290

  Ha, Minghao ^a   Zhang, Guotong ^a   Diao, Shu ^a   Lin, Mingfang ^a   Sun, Liping ^a   She, Huiyuan ^a   Kuan, Chenbao ^a   Shen, Lihui ^a   Huang, Chunhong ^a   Shen, Wenjuan ^a   Huang, Zhongming ^a  

^a Shanghai No 7 hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; STATISTICS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIROLOGY;

ADENINE; ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84856392164     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1163-0     Document Type: Article

References (22)

1. Hepatitis B fact sheet no. 204. (2000) Geneva: World Health Organization, October 2000.
2. Hadziyannis SJ (1995) Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1: 7-36.
3. Funk ML, Rosenberg DM, Lok AS (2002) World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 9: 52-61.
4. Brunetto MR, Stemler M, Schodel E et al (1989) Identification of HBV variants which can not produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 21: 151-154.
5. Proceedings of the European Association for the Study of the Liver (EASL) (2003) International consensus conference on hepatitis B, September 14-16, 2002. J Hepatol 39(Suppl 1): S1-S235.
6. Wai CT, Lok AS (2002) Treatment of hepatitis B. J Gastroenterol 37: 771-778.
7. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C (2000) Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32: 847-851.
8. European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50: 227-242.
9. Richman DD (2000) The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 32: 866-867.
10. Liaw YF, Leung N, Kao JH et al (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2: 263-283.
11. Lindh M, Andersson AS, Gusdal A (1997) Genotypes, nt1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J Infect Dis 175: 1285-1293.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al (2005) Long-term therapy with Adefovir Dipivoxil for HBeAg-Negative chronic hepatitis B. N Engl J Med 352: 2673-2681.
13. Fung SK, Wong F, Hussain M et al (2004) Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 11: 432-438.
14. Huang YH, Wu JC, Chang TT et al (2003) Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 10: 277-284.
15. Wang L, Liu F, Liu YD et al (2010) Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat 17: 298-304.
16. Song BC, Suh DJ, Lee HC et al (2000) Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32: 803-806.
17. Liu F, Wang L, Li XY et al (2011) Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroentol Hepatol 26: 456-460.
18. Liang Y, Jiang J, Su M et al (2011) Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 34: 344-352.
19. Shin JW, Park NH, Park JH et al (2005) Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B. J Viral Hepat 12: 393-397.
20. Ryu SH, Chung YH, Choi MH et al (2003) Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospectivestudy. J Hepatol 39: 614-619.
21. Lee HC, Suh DJ, Ryu SH et al (2003) Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 52: 1779-1783.
22. Zeng G, Wang Z, Wen S et al (2005) Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 12: 609-617.